IP Library Granted Patent US 7,632,929
Granted Patent B2
US 7,632,929 · App. 11/733,085 · Granted Dec 15, 2009

Methamphetamine-like hapten compounds, linkers, carriers and compositions and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,632,929
App. No.
11/733,085
Granted
Dec 15, 2009
Kind
B2
Abstract

The invention generally relates to hapten compounds comprising either (+) methamphetamine or (+) amphetamine conjugated to a linker. Generally speaking, hapten compounds of the invention may be used to elicit an immune response to one or more of (+) methamphetamine, (+) amphetamine, or (+) MDMA.

Claims (13)

1. A compound of formula (I):

wherein:

R 1 is selected from the group consisting of hydrogen and methyl; and

L is selected from the group consisting of O(CH 2 ) 5 attached to the benzene ring at the meta position and O(CH 2 ) 9 attached to the benzene ring at the meta position.

2. A composition comprising a compound of formula (I), as claimed in claim 1 , wherein L is selected from the group consisting of O(CH 2 ) 5 attached to the benzene ring at the meta position, and O(CH 2 ) 9 attached to the benzene ring at the meta position.

3. The composition of claim 2 , further comprising an adjuvant.

4. The composition of claim 3 , wherein the adjuvant is pharmaceutically acceptable for use in a human subject.

5. The composition of claim 3 , wherein the adjuvant is selected from the group consisting of alum, TiterMax Gold, Ribi, ASO4, Freund's complete adjuvant, and Freund's incomplete adjuvant.

6. The composition of claim 3 , further comprising a pharmaceutically acceptable carrier.

7. The composition of claim 6 , wherein the pharmaceutically acceptable carrier is a bacterial toxin or a bacterial toxoid.

8. The composition of claim 3 , further comprising a pharmaceutically acceptable excipient.

9. The compound of claim 1 , wherein L is O(CH 2 ) 9 attached to the benzene ring at the meta position and R 1 is methyl.

10. The compound of claim 1 , wherein L is O(CH 2 ) 5 attached to the benzene ring at the meta position and R 1 is methyl.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 4, 2018
From: BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
To: BIOVENTURES, LLC
Reel/Frame 047667/0515 →
CONFIRMATORY LICENSE Recorded Oct 29, 2010
From: UNIVERSITY OF ARKANSAS MED SCIS LTL ROCK
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 025217/0071 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 22, 2007
From: OWENS, SAMUEL M.; CARROLL, FRANK IVY; ABRAHAM, PHILIP
To: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS
Reel/Frame 019469/0499 →